364342-32-5

Basic information

• Product Name: 4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide
• Synonyms: 4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide
• CAS NO: 364342-32-5
• Molecular Weight: 720.096
• Mol File: 364342-32-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide(364342-32-5)
• EPA Substance Registry System: 4-bromo-N-(2-(4-bromobenzylideneamino)-1,2-(4-bromophenyl)ethyl)benzamide(364342-32-5)

Safety Data

• Hazardous Substances Data: 364342-32-5(Hazardous Substances Data)

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 117903-53-4 meso-1,2-bis(4-bromophenyl)-1,2-ethanediamine 

Relevant articles and documents

Synthesis and evaluation of an imidazole derivative-fluorescein conjugate

The murine double minute (MDM2) oncogene a negative regulator of protein 53 (p53) tumor suppressor, is found overexpressed in many different types of cancer and the interaction between MDM2 and p53 has become the target of intensive research. MDM2 inhibitors represent a promising class of p53 activating compounds that may be effective in cancer treatment and diagnostic imaging. Nutlins, a family of cis-imidazoline analogues and small-molecule MDM2 antagonists, have the potential use in cancer therapies. We have synthesized an imidazole derivative (Nutlin-Glycine) conjugated to the commonly used fluorophore, 6-carboxyfluorescein (FAM) and evaluated its possible use as an imaging agent. Cellular uptake studies demonstrated that the fluorescence intensity in human osteosarcoma (SJSA-1) and colon carcinoma (HCT116) cells were significantly increased with the treatment of Nutlin-Glycine-FAM when compared with FAM (control). Blocking studies also confirmed that our imidazole-fluorescein conjugate may be a good candidate for imaging tumors, suggesting the need for further in vivo evaluation by positron emission tomography.